What is Engitix?
Founded in 2016 and headquartered in London, Engitix has pioneered a proprietary human extracellular matrix (ECM) drug discovery platform. This innovative technology enables the identification of novel drug targets, with the company having already established a portfolio of programs targeting fibrosis and solid tumors. Engitix's platform has also facilitated two significant partnerships, demonstrating its value and potential within the biopharmaceutical sector. The company's focus on the ECM, a critical component of tissue structure and function, positions it to address complex diseases with unmet medical needs.
How much funding has Engitix raised?
Engitix has raised a total of $85.2M across 2 funding rounds:
Series A
$60.2M
Series A
$25M
Series A (2022): $60.2M with participation from Dompé farmaceutici S.P.A and Netherton Investments
Series A (2026): $25M, investors not publicly disclosed
Key Investors in Engitix
Dompé farmaceutici S.P.A
Dompé farmaceutici S.P.A is an Italian biopharmaceutical company with a broad therapeutic focus, likely investing in Engitix to explore synergistic opportunities in drug discovery and development, particularly within oncology and fibrosis.
Netherton Investments
Netherton Investments is likely a private investment firm or family office that provides capital for growth-stage companies, potentially focusing on the healthcare and biotechnology sectors.
What's next for Engitix?
With the recent influx of major strategic investment and a robust total funding base of $85.2M, Engitix is poised for significant expansion. The company is expected to leverage this capital to further advance its drug discovery engine, potentially scaling its research and development operations and progressing its existing programs through preclinical and clinical stages. The strategic nature of the recent financing suggests a focus on accelerating market entry and solidifying key partnerships. Engitix's trajectory indicates a strong commitment to translating its pioneering ECM platform into impactful therapies for challenging diseases.
See full Engitix company page
